Executive Summary of Final Report

**Sino-implant (II) Initiative: 2010 Quality Assurance Evaluation**

December 15, 2010

Submitted by:

FHI

Markus Steiner, Ph.D.
Sino-implant (II) Project Director
Family Health International
P.O. Box 13950
Research Triangle Park, NC 27709
Tel: +1.919.544.7040
FAX: +1.919.544.7261
Executive Summary of Final Report


David W. Jenkins, Ph.D.
Associate Scientist II
Product Quality and Compliance Division
2810 Meridian Parkway, Suite 110
Durham, NC 27713
E-mail: djenkins@fhi.org
Phone: 919-544-7040 ext. 11617
Fax: 919-544-5849

Derek H. Owen, Ph.D.
Scientist I
Clinical Sciences
2224 E. NC Hwy. 54, Durham NC 27713
E-mail: acancel@fhi.org
Telephone: 919-544-7040 ext. 11586
Fax: 919-544-7261

Markus Steiner, Ph.D.
Sino-implant (II) Project Director
Clinical Sciences
2224 E. NC Hwy. 54, Durham NC 27713
E-mail: msteiner@fhi.org
Telephone: 919-544-7040 ext. 11346
Fax: 919-544-7261
Table of Contents for Final Report

Final Report ..................................................................................................................................... i
Executive Summary ....................................................................................................................... iv
Introduction ..................................................................................................................................... 1
Section I: Quality Assurance Monitoring of Sino-implant (II) ....................................................... 2
  Brief Description of Sino-implant (II) Commercial Lot Release Testing .............................. 2
  Results of Sino-implant (II) Commercial Lot Release Verification ....................................... 3
  Conclusion of 2010 Quality Assurance Monitoring of Commercial Lots of Sino-implant (II) ................................................................................................................................................. 3
Section II: Annual Quality Assurance Evaluation of Sino-implant (II) ......................................... 4
  Levonorgestrel: Active Pharmaceutical Ingredient (API) Quality Assurance Evaluation ....... 4
    Levonorgestrel CP Evaluation ................................................................................................. 4
    Levonorgestrel USP/BP Evaluation ..................................................................................... 5
  Conclusion of Levonorgestrel: Active Ingredient Quality Assurance Evaluation.................. 8
  Sino-implant (II): Final Product Quality Assurance Evaluation ................................................. 9
    Sino-implant (II) Sample Lot Release Verification ................................................................. 9
    Ethylene Oxide Residuals Evaluation ................................................................................... 10
    Inorganic Impurities Evaluation ......................................................................................... 11
    Residual Solvents Evaluation ............................................................................................. 15
    Bacterial Endotoxin Evaluation .......................................................................................... 16
    Cytotoxicity Evaluation ...................................................................................................... 17
  Sino-implant (II): Packaging Material Evaluation .................................................................... 18
    Packaging Physicochemical Evaluation ............................................................................ 18
    Package Integrity Evaluation .............................................................................................. 19
Section III: Summary of Results of the 2010 Comprehensive Quality Assurance Evaluation .... 20
Tables for Final Report

Table 1. Summary of the quality assurance evaluation of Sino-implant (II)................................. v
Table 2. Sino-implant (II) commercial lot release verification test results................................... 3
Table 3. Levonorgestrel: lot release verification test results analyzed using the Chinese Pharmacopeia monograph............................................................................................................... 5
Table 4. Levonorgestrel: lot release verification test results analyzed using the USP monograph.......................................................................................................................................................... 6
Table 5. Levonorgestrel: lot release verification test results analyzed using the BP monograph. 7
Table 6. Sino-implant (II) sample lot release verification results................................................. 9
Table 7. Ethylene oxide residuals test results of Sino-implant (II)................................................ 10
Table 8. ICP-MS test results of Sino-implant (II): USP inorganic impurities (Heavy Metals)... 13
Table 9. ICP-MS test results of Sino-implant (II): additional inorganic impurities. ................... 14
Table 10. Residual solvents test results of Sino-implant (II). ....................................................... 16
Table 11. Limulus Amebocyte Lysate Test (Kinetic Turbidimetric Technique) test results of Sino-implant (II). ........................................................................................................................ 16
Table 12. MEM elution test results of Sino-implant (II). ............................................................. 17
Table 13. Physicochemical test results of Sino-implant (II) packaging film.............................. 18
Table 14. Bubble emission test results of Sino-implant (II). ....................................................... 19
Table 15. Comprehensive tabulated summary of the quality assurance results of Sino-implant (II) tests conducted............................................................... 20
Executive Summary

A quality assurance evaluation and monitoring program was implemented by FHI to verify that Sino-implant (II) meets lot release specifications for the product. This report expands on the results obtained after the initial quality assurance evaluation and monitoring program conducted in 2008 and 2009.

Commercial lot release testing verification was conducted for all four lots of Sino-implant (II) that were shipped to countries as part of the Sino-implant (II) introduction in developing countries. In all instances results were in compliance with Sino-implant (II) lot release specifications (Table 1).

A more extensive battery of tests was conducted to evaluate if Sino-implant (II) meets international quality standards. The battery of tests selected was based on standards from the United States Pharmacopeia (USP), British Pharmacopeia (BP), International Organization for Standardization (ISO) and the American Society for Testing and Materials (ASTM). Sino-implant (II) samples tested met the quality requirements for all tests conducted (Table 1).

We conclude that Shanghai Dahua Pharmaceutical Co., Ltd continues to demonstrate the ability to consistently produce a contraceptive implant that meets international quality standards.
Table 1. Summary of the quality assurance evaluation of Sino-implant (II)

<table>
<thead>
<tr>
<th>Test</th>
<th>Lot #</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Quality Assurance Monitoring of Sino-implant (II)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sino-implant (II): Commercial Lot Release Testing Verificationa</td>
<td>08312009 04112010 07092010 08042010</td>
<td>Met requirements</td>
</tr>
<tr>
<td>Annual Quality Assurance Evaluation of Sino-implant (II)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Levonorgestrel: Active Ingredient Quality Assurance Evaluation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Levonorgestrel: China Pharmacopeia Evaluationa</td>
<td>ZQ20090013 ZQ20090023 ZQ20090024</td>
<td>Met requirements</td>
</tr>
<tr>
<td>Levonorgestrel: British Pharmacopeia Evaluationa</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sino-implant(II): Final Product Quality Assurance Evaluation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sample Lot Release Verificationa</td>
<td>08312009 091207 100104</td>
<td>Met requirements</td>
</tr>
<tr>
<td>Ethylene Oxide Residuals Evaluationb</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inorganic Impurities Evaluationc</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Residual Solvents Evaluationd</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bacterial Endotoxin Evaluationb</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cytotoxicity Evaluationb</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sino-implant(II): Packaging Material Evaluation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Packaging Physicochemical Evaluationb</td>
<td>09-1143-09-10-22-1 09-1217-09-11-16-1</td>
<td>Met requirements</td>
</tr>
<tr>
<td>Sino-implant (II): Package Integrity Evaluationb</td>
<td>08312009 091207 100104</td>
<td>Met requirements</td>
</tr>
</tbody>
</table>

a Conducted by SGS Life Sciences Division, Shanghai, China
b Conducted by Nelson Laboratories, Inc., Salt Lake City, UT
c Conducted by Cyanta Analytical Services, Maryland Heights, MO
d Conducted by Irvine Pharmaceutical Sciences, Irvine, CA
e Conducted by Lancaster Laboratories, Lancaster, PA